ATE207351T1 - Verwendung vonmodafinil zur behandlung von atemstillstand im schlaf und zentral erregten atembeschwerden - Google Patents

Verwendung vonmodafinil zur behandlung von atemstillstand im schlaf und zentral erregten atembeschwerden

Info

Publication number
ATE207351T1
ATE207351T1 AT94919708T AT94919708T ATE207351T1 AT E207351 T1 ATE207351 T1 AT E207351T1 AT 94919708 T AT94919708 T AT 94919708T AT 94919708 T AT94919708 T AT 94919708T AT E207351 T1 ATE207351 T1 AT E207351T1
Authority
AT
Austria
Prior art keywords
modafinil
respiracy
pct
breathing discomfort
treat sleeping
Prior art date
Application number
AT94919708T
Other languages
German (de)
English (en)
Inventor
Philippe Laurent
Original Assignee
Lafon Labor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9448411&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE207351(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lafon Labor filed Critical Lafon Labor
Application granted granted Critical
Publication of ATE207351T1 publication Critical patent/ATE207351T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrotherapy Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Control Of Throttle Valves Provided In The Intake System Or In The Exhaust System (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT94919708T 1993-06-22 1994-06-14 Verwendung vonmodafinil zur behandlung von atemstillstand im schlaf und zentral erregten atembeschwerden ATE207351T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9307555A FR2706767B1 (enExample) 1993-06-22 1993-06-22
PCT/FR1994/000711 WO1995000132A1 (fr) 1993-06-22 1994-06-14 Utilisation du modafinil pour le traitement des apnees du sommeil et troubles ventilatoires d'origine centrale

Publications (1)

Publication Number Publication Date
ATE207351T1 true ATE207351T1 (de) 2001-11-15

Family

ID=9448411

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94919708T ATE207351T1 (de) 1993-06-22 1994-06-14 Verwendung vonmodafinil zur behandlung von atemstillstand im schlaf und zentral erregten atembeschwerden

Country Status (14)

Country Link
US (1) US5612379A (enExample)
EP (1) EP0705099B1 (enExample)
JP (1) JP3703831B2 (enExample)
KR (1) KR100315389B1 (enExample)
AT (1) ATE207351T1 (enExample)
AU (1) AU684087B2 (enExample)
CA (1) CA2165824C (enExample)
DE (1) DE69428791T2 (enExample)
DK (1) DK0705099T3 (enExample)
ES (1) ES2165878T3 (enExample)
FR (1) FR2706767B1 (enExample)
HU (1) HU216731B (enExample)
PT (1) PT705099E (enExample)
WO (1) WO1995000132A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618845A (en) 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
JP2002504510A (ja) 1998-02-27 2002-02-12 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ 睡眠時無呼吸に対する処置のための、セロトニン関連活性を有する薬剤
US7160898B2 (en) * 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
US20060241164A1 (en) * 1998-02-27 2006-10-26 The Board Of Trustees Of The University Of Illinoi Pharmacological treatment for sleep apnea
US6492396B2 (en) 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
JP4593074B2 (ja) * 2000-10-11 2010-12-08 セフアロン・インコーポレーテツド モダフィニル化合物含有組成物
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
US7297346B2 (en) * 2001-05-25 2007-11-20 Cephalon Inc. Pharmaceutical formulations of modafinil
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040048931A1 (en) 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
US6992219B2 (en) * 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
IL153098A0 (en) * 2002-11-26 2003-06-24 Chemagis Ltd Pharmaceutical compositions containing modafinil
US7528172B2 (en) * 2003-01-21 2009-05-05 The Cooper Health System, Inc. Compositions and methods for improving recovery after general anesthesia
ES2487415T3 (es) * 2003-03-17 2014-08-20 Neurohealing Pharmaceuticals, Inc. Tratamiento dopaminérgico de alta potencia de deficiencias neurológicas asociadas con lesiones cerebrales
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
AR045423A1 (es) * 2003-05-13 2005-10-26 Cephalon Inc Combinaciones de analiticos y antidepresivos
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
US7119214B2 (en) * 2004-04-13 2006-10-10 Cephalon France Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
EP1586560A1 (en) * 2004-04-13 2005-10-19 Cephalon, Inc. Thio-substituted arylmethanesulfinyl derivatives
US7423176B2 (en) * 2004-04-13 2008-09-09 Cephalon, Inc. Bicyclic aromatic sulfinyl derivatives
US7449481B2 (en) * 2004-04-13 2008-11-11 Cephalon, Inc. Thio-substituted biaryl-methanesulfinyl derivatives
US7314875B2 (en) * 2004-04-13 2008-01-01 Cephalon, Inc. Tricyclic aromatic and bis-phenyl sulfinyl derivatives
US7297817B2 (en) * 2004-04-13 2007-11-20 Cephalon France Thio-substituted arylmethanesulfinyl derivatives
WO2006069030A1 (en) * 2004-12-20 2006-06-29 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
AU2006272874B2 (en) * 2005-07-21 2010-03-11 Neurohealing Pharmaceuticals, Inc. Rapid onset and short term modafinil compositions and methods of use thereof
BRPI0714173A2 (pt) * 2006-07-12 2012-12-25 Elan Pharma Int Ltd composiÇço nanoparticulada estÁvel,mÉtodos para preparar a composiÇço, para prevenir e/ou tratar estados de doenÇas, sintomas, sÍndromes e condiÇÕes do sistema nervoso central, para melhorar ou manter a biodisponibilidade de modafinil, e para tratar distérbio com base neurolàgica, composiÇço farmacÊutica, e forma de dosagem
JP5395663B2 (ja) 2006-08-14 2014-01-22 ニューロヒーリング・ファーマシューティカルズ・インコーポレーテッド モダフィニルによる早漏の治療
US20080181966A1 (en) * 2006-10-18 2008-07-31 Cephalon, Inc. Modafinil pharmaceutical compositions
CN101641090B (zh) * 2006-12-19 2012-12-05 亚勒斯有限公司 莫达非尼在制备治疗多动腿综合征的药物中的应用
AU2011203970A1 (en) * 2010-01-07 2012-07-12 Vivus, Inc. Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent
ES2871381T3 (es) 2013-08-30 2021-10-28 Green Cross Wellbeing Corp Composición para prevenir y tratar la fatiga relacionada con el cáncer, que contiene polvo de ginseng procesado o extracto de ginseng procesado que tiene un componente de ginsenósido mejorado
US9616068B2 (en) 2014-10-27 2017-04-11 Pohela LLC Animal training using cognitive enhancement

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1584462A (en) * 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2663225B1 (fr) * 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
FR2684875B1 (fr) * 1991-12-13 1995-05-24 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique.
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
KR100315389B1 (ko) 2002-02-19
JP3703831B2 (ja) 2005-10-05
WO1995000132A1 (fr) 1995-01-05
CA2165824C (fr) 2005-08-02
KR960703009A (ko) 1996-06-19
PT705099E (pt) 2002-03-28
AU7076094A (en) 1995-01-17
CA2165824A1 (fr) 1995-01-05
DE69428791D1 (de) 2001-11-29
EP0705099A1 (fr) 1996-04-10
EP0705099B1 (fr) 2001-10-24
JPH09500374A (ja) 1997-01-14
HU216731B (hu) 1999-08-30
ES2165878T3 (es) 2002-04-01
AU684087B2 (en) 1997-12-04
FR2706767A1 (enExample) 1994-12-30
DE69428791T2 (de) 2002-07-04
HUT74674A (en) 1997-01-28
US5612379A (en) 1997-03-18
HU9503702D0 (en) 1996-02-28
DK0705099T3 (da) 2002-02-11
FR2706767B1 (enExample) 1995-09-08

Similar Documents

Publication Publication Date Title
ATE207351T1 (de) Verwendung vonmodafinil zur behandlung von atemstillstand im schlaf und zentral erregten atembeschwerden
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE69317578D1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
ATE262895T1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
DE60207383D1 (de) Ibuprofen und diphenhydramin enthaltende zusammensetzungen und deren verwendung zur behandlung von schlafstörungen
DE59409832D1 (de) Pflaster zur behandlung von nagelmykosen
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE69527052D1 (de) Verwendung von Wasser mit verringertem Deuterium-Gehalt zur Herstellung von hygienischen und kosmetischen Präparaten
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE241981T1 (de) Verwendung von 4-aminopyridin zur behandlung von schmerz und spastik folgende einer verletzung des rückenmarks
ATE159937T1 (de) 1,4-disubstituierte piperazine zur behandlung von asthma und entzündungen der atemwege
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
ATE289816T1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE190839T1 (de) Verwendung von prodelphidinen zur behandlung von arthrose
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
ATE408602T1 (de) Monohyroxycarbamezepin zur verwendung bei der herstellung eines medikaments zur behandlung von affektiver psychose, aufmerksamkeits störungen und neuropathischen schmerzen
ATE239458T1 (de) Verwendung von selegilin zur behandlung von epileptischen erkrankungen
ATE200624T1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
DE50105253D1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
ATE186640T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung neurogenerativer erkrankungen
DE59409813D1 (de) Imidazolochinoxalinone zur behandlung zentralnervöser erkrankungen
ATE245432T1 (de) Verwendung von extrakten aus ginkgo-biloba- blättern zur behandlung von schlafstörungen
DE60022317D1 (de) Verwendung von fluorierten triazolen zur behandlung von neuropathischem schmerz

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification